Scholar-in-Training Awards

The AACR is proud to offer Scholar-in-Training Awards to enable the participation of meritorious early-career scientists at the Annual Meeting 2016. Since its inception in 1986, the AACR Annual Meeting Scholar-in-Training Award program has provided more than 4,700 grants to young investigators and has received support from more than 40 cancer research foundations, corporations, individuals and other organizations dedicated to the fight against cancer. This year, seventeen organizations or individuals generously provided the funding to support this program.

The names and affiliations of the 2016 Scholar-in-Training Award recipients, along with the numbers and titles of their presentations, are listed below.

2016 AACR-AbbVie Scholar-in-Training Awards

AbbVie has graciously donated funds to support early-career investigators who will be presenting meritorious proffered papers at the AACR Annual Meeting 2016.


Prashanth R. Gokare, MS, Fox Chase Cancer Center, Philadelphia, PA. Abstract 3706. p53 represses pyrimidine catabolic gene dihydropyrimidine dehydrogenase (DPYD) expression following thymidylate synthase (TS) inhibition.

Majda Haznadar, PhD, National Cancer Institute, Bethesda, MD. Abstract 4320. Circulating vitamin D2 and D3 levels and single nucleotide polymorphism associations with lung cancer status: A case-control study.

Yuh-Charn Lin, PhD, Academia Sinica, Taipei, Taiwan. Abstract 3391. SCUBE2 is a co-receptor for VEGFR2 in tumor angiogenesis.

Robbie G. Majzner, MD, National Cancer Institute, Bethesda, MD. Abstract 2648. Chimeric antigen receptor T-cell therapy against anaplastic lymphoma kinase (ALK) is limited by target antigen density and CAR surface expression.


Pedro Torres-Ayuso, PhD, Cancer Research UK Manchester Institute, Manchester, United Kingdom. Abstract 4408. Mutant ABL1 is a genetic dependency in non-small cell lung cancer amenable to pharmacological intervention.

Xiaoliang Wang, MPH, University of Washington, Seattle, WA. Abstract 4284. Exploratory plasma proteomic analysis in a randomized cross-over trial of aspirin among healthy individuals.

Yu Zheng, PhD, MGH Cancer Center, Charlestown, MA. Abstract 2679. Induction of β-globin protects circulating tumor cells from oxidative stress during dissemination.

Mark W. Zimmerman, PhD, Dana-Farber Cancer Institute, Boston, MA. Abstract 2433. Loss of chd5-mediated gene repression synergizes with MYCN to accelerate neuroblastoma tumorigenesis in zebrafish.

2016 AACR- American Brain Tumor Association Scholar-in-Training Awards

The American Brain Tumor Association has graciously donated funds to support young investigators who will be presenting high-quality proffered papers in brain cancer research at the AACR Annual Meeting 2016.

Allison R. Hanaford, BS, Johns Hopkins University School of Medicine, Baltimore, MD. Abstract 2476. DiSCovering innovative therapies for rare tumors: Combining genetically accurate disease models with advanced in silico analysis to identify novel therapeutic targets.


Marco Mineo, PhD, Brigham and Women's Hospital/Harvard Medical School, Boston, MA. Abstract 1000. The long non-coding RNA HIF1A-AS2 regulates mesenchymal glioma stem cell tumorigenicity.

Gilbert J. Rahme, MSc, Norris Cotton Cancer Center, Lebanon, NH. Abstract 1891. PDGF signaling maintains survival of proneural glioma cells by regulating USP1 to stabilize ID2.

Arun Kumar Rooj, PhD, Brigham and Women's Hospital/Harvard Medical School, Boston, MA. Abstract 1929. The novel role of microRNA-128 in proneural to mesenchymal subtype transition in glioblastoma stem cells by targeting components of pro-oncogenic Polycomb Repressor Complex.
2016 AACR-Aflac, Inc. Scholar-in-Training Awards

Support for AACR Scholar-in-Training Awards is part of Aflac’s generous support of activities for early-career scientists within the AACR. These awards are for AACR Associate Members presenting outstanding proffered papers at the AACR Annual Meeting 2016.

**Stefano Annunziato, MSc**, NKI-AVL, Amsterdam, Netherlands. **Abstract 2687.** Rapid in vivo testing of tumor suppressors in ILC by CRISPR-Cas9 mediated somatic gene editing of the mammary gland.

**Alice H. Berger, PhD**, Broad Institute, Cambridge, MA. **Abstract 4368.** High-throughput phenotyping of lung cancer somatic mutations.

**Megha Chandrashekhar, MSc**, Donnelly Center for Cellular and Biomolecular Research, University of Toronto, Toronto, ON, Canada. **Abstract 233.** Identification of cancer vulnerabilities to metabolic perturbation using genome wide CRISPR screens.

**Elizabeth A. Coker, BA, MSci**, The Institute of Cancer Research, London, United Kingdom. **Abstract 4383.** SOCRATES: integrating ex vivo and in silico analysis to identify optimal drug combinations for patients.

**Julie M. Diamond, MS**, NYU School of Medicine, New York, NY. **Abstract 1648.** Ionizing radiation switches the function of tumor-derived exosomes from messengers of tolerance to inducers of antitumor immunity.

**Georg Fluegen, MD**, University Hospital Düsseldorf, Düsseldorf, Germany. **Abstract 4394.** Phenotypic heterogeneity of disseminated tumor cells is predetermined by primary tumor hypoxic microenvironments.

**Michael V. Gormally, MPhil**, National Center for Advancing Translational Sciences (NCATS), Bethesda, MD. **Abstract 3088.** Transcription factor as target: Novel small molecule inhibits FOXM1 DNA binding and oncogenic gene products.

**Andrew W. Holle, PhD**, Max Planck Institute for Intelligent Systems, Stuttgart, Germany. **Abstract 5059.** Cancer cell invasion dynamics in microchannels during stromal cell coculture.


**Sita Kugel, PhD**, Massachusetts General Hospital Cancer Center, Boston, MA. **Abstract 2656.** Loss of SIRT6 reactivates the oncofetal RNA-binding protein Lin28b to drive pancreatic cancer.
Alice W. Lee, MPH, University of Southern California, Los Angeles, CA. Abstract 797. A splicing variant of TERT identified by GWAS interacts with menopausal estrogen therapy in risk of ovarian cancer.

Nina Linde, Dr. rer. nat., Mt. Sinai Icahn School of Medicine, New York, NY. Abstract 3233. Macrophages orchestrate early dissemination of HER2+ cancer cells.

Riadh Lobbardi, PhD, Massachusetts General Hospital, Charlestown, MA. Abstract 3583. Thymocyte selection-associated HMG box protein (TOX) induces genomic instability in T-cell acute lymphoblastic leukemia.

Janet L. Markman, MS, Cedars Sinai Medical Center, Los Angeles, CA. Abstract 1459. Revealing the underlying causes of the gender disparity in melanoma: Role of testosterone.

Rina M. Mbofung, BS, The University of Texas MD Anderson Cancer Center, Houston, TX. Abstract 4360. Inhibition of HSP90 enhances T cell-mediated antitumor immune responses through expression of interferon-alpha response Genes.

Takuro Noguchi, MD, PhD, Washington University in St. Louis, St. Louis, MO. Abstract 903. IFN-γ induced PD-L1 on tumor and host cells co-operatively prevents tumor immune elimination after cancer immunoediting.


Elena Piskounova, PhD, Children's Research Institute at UTSW Medical Center, Dallas, TX. Abstract 2806. Oxidative stress limits metastasis of human melanoma cells.


Idit Sagiv-Barfi, PhD, Stanford University, Stanford, CA. Abstract 551. In situ vaccination with TLR9 agonist and anti-Ox40 antibody is sufficient to induce abscopal responses even in mice with spontaneous oncogene-driven tumors.

Laura M. Spring, MD, Massachusetts General Hospital, Boston, MA. Abstract 1439. Pathological complete response after neoadjuvant chemotherapy predicts improved survival in all major subtypes of breast cancer: systematic review and meta-analyses of over 18,000 patients.


Melanie Weigert, BSc, University of Glasgow, Glasgow, United Kingdom. Abstract 3549. The role of programed necrosis in oncolytic adenovirus-induced cell death in ovarian cancer.
Anna Wojtuszkiewicz, Msc, VU Medical Center, Amsterdam, Netherlands. **Abstract 4336.** Spliceosome inhibition as a novel therapeutic option in acute leukemia.

Hanseul Yang, MS, The Rockefeller University, New York, NY. **Abstract 881.** Dissecting chromatin dynamics in malignant progression.

### 2016 AACR-June L. Biedler Scholar-in-Training Award

These awards are for meritorious proffered papers in the field of drug resistance to be presented at the AACR Annual Meeting 2016. These awards are made possible through the Estate of Dr. June L. Biedler and shall be used in part to increase public understanding of basic cancer research. The late Dr. Biedler was a dedicated member of AACR and a distinguished scientist at Memorial Sloan Kettering Cancer Center. Dr. Biedler believed that science communication is a cornerstone to the acceleration of progress.


Eric E. Gardner, PharmD, Johns Hopkins University School of Medicine, Baltimore, MD. **Abstract 4187.** Loss of SLFN11 or gain of TWIST1 promote chemotherapy resistance in small cell lung cancer.

Joao F. Incio, MD, Harvard Medical School/MGH, Boston, MA. **Abstract 898.** Obesity-induced inflammation and desmoplasia promote pancreatic cancer progression and resistance to chemotherapy.

Elisa Lazzari, PhD, Moores Cancer Center at University of California, San Diego, San Diego, CA. **Abstract 2414.** ADAR1-dependent RNA editing is a mechanism of therapeutic resistance in human plasma cell malignancies.

Vanessa S. Rodrik-Outmezguine, PhD, Memorial Sloan Kettering Cancer Center, New York, NY. **Abstract 2147.** Overcoming mTOR resistance mutations with a new generation mTOR inhibitor.

Zhe Wang, PhD, The University of Texas MD Anderson Cancer Center, Houston, TX. **Abstract 1441.** Systems-level interrogation of resistance mechanisms to immunotherapy through pooled shRNA screens.
2016 AACC-Bristol-Myers Squibb Oncology Scholar-in-Training Awards

Bristol-Myers Squibb Oncology has graciously donated funds to support early-career investigators who will be presenting meritorious proffered papers at the AACR Annual Meeting 2016.

Nicole M. Aiello, BS, University of Pennsylvania, Philadelphia, PA. Abstract 2676. Epithelial-mesenchymal transition does not require transcriptional repression of the epithelial program in vivo.

Noemi Andor, PhD, Stanford University, Palo Alto, CA. Abstract 2387. Pan-cancer analysis of clonal evolution reveals the costs and adaptive benefits of genomic instability.

Rouf Banday, MSc, PhD, National Cancer Institute, NIH, Gaithersburg, MD. Abstract 2562. Bladder cancer GWAS signal at 4p16.3 affects response of TMEM129 to chemically-induced endoplasmic reticulum stress.

Victoria H. Burton, BS, UT Southwestern, Dallas, TX. Abstract 22. Investigating the functional contribution of TANK binding kinase 1 to inflammation induced disease progression.

Laura Cato, PhD, Dana-Farber Cancer Institute, Boston, MA. Abstract 864. Androgen receptor stability in prostate cancer is regulated by the cochaperone Bag-1L.

Randy J. Giedt, PhD, Massachusetts General Hospital/ Harvard Medical School, Boston, MA. Abstract 234. Mitochondrial morphology as a biomarker of cancer phenotype and drug response.

Yi-Nan Li, BS, National Tsing Hua University, Hsinchu City, Taiwan. Abstract 1575. Intratumoral injection of interleukin-17 inhibits distant metastasis of radiation-induced recurrent tumor.


Alexander T. Pearson, MD, PhD, University of Michigan, Ann Arbor, MI. Abstract 2705. A computational algorithm to predict tumor growth and cancer stem cell proportion in vitro and in vivo from single-cell observations.

Jeanne A. Pierzynski, MPH, The University of Texas MD Anderson Cancer Center, Houston, TX. Abstract 816. Genetic variants in the dopaminergic system and bladder cancer clinical outcomes.

Ho Lam Tang, PhD, Johns Hopkins University Bloomberg School of Public Health, Baltimore, MD. Abstract 3495. Tracking reversal of apoptosis after caspase activation in cancer cells.

Xi Tian, PhD, University of North Carolina-Chapel Hill, Chapel Hill, NC. Abstract 4264. Engineered in vitro models of cancer metastasis using decellularized biomatrix.
Mary Topalovski, BS, University of Texas Southwestern Medical Center, Dallas, TX. Abstract 5093. Fibulin-5 supports pancreatic tumor growth through inhibition of integrin-induced ROS.

Chengqian Yin, BS, Drexel University, Philadelphia, PA. Abstract 2802. Exogenous pyruvate supports oxygen-independent tumor cell proliferation by serving as an oxygen surrogate to maintain homeostasis of NAD+/NADH.

2016 AACR-Gerald B. Grindey Memorial Scholar-in-Training Awards

These awards are presented to meritorious proffered papers in the field of preclinical science presented at the AACR Annual Meeting 2016. The late Dr. Grindey was a dedicated member of the AACR and a distinguished scientist at Eli Lilly and Company. The Gerald B. Grindey Memorial Fund was established in his honor and has been entrusted to the AACR to be used toward educational programs for early-career scientists engaged in preclinical cancer research.

Ian S. Goldlust, MS, NIH/NCATS, Bethesda, MD. Abstract 278. No cell left behind: Residual ovarian spheroids drive recurrence and are sensitive to the pro-oxidant elesclomol.

Jonathan W. Pollock, BS, University of Michigan, Ann Arbor, MI. Abstract 3898. Structure-based optimization of small molecule inhibitors of the protein-protein interaction between menin and mixed lineage leukemia (MLL).

2016 AACR-GYRIG Scholar-in-Training Awards

Get Your Rear in Gear Philadelphia has graciously donated funds to the AACR to support early-career investigators who will be presenting meritorious proffered papers relating to colorectal cancer research at the AACR Annual Meeting 2016.

Mahdi Fallah, MD, PhD, German Cancer Research Center (DKFZ), Heidelberg, Germany. Abstract 2556. Family history of colorectal cancer in half-siblings as important as in siblings.

Matthew P. Hanley, BS, University of Connecticut Health Center, Farmington, CT. Abstract 899. Cancer protection associated with dietary methyl donor deficiency is characterized by persistent changes to epithelial proliferation and metabolism.

Keehoon Jung, PhD, Harvard Medical School / MGH, Boston, MA. Abstract 4195. Targeting the immune microenvironment to improve colorectal cancer anti-angiogenic therapy.
Billy T. Lau, PhD, Stanford School of Medicine, Stanford, CA. Abstract 3603. Megabase-scale determination of complex genetic aberrations of primary cancer genomes at individual DNA molecule resolution.

Wojciech Senkowski, MSc, Uppsala University, Uppsala, Sweden. Abstract 213. Mitochondrial inhibitors and statins: a lethal combination for metabolically stressed cancer cells.

Chelsie K. Sievers, BS, University of Wisconsin, Madison, WI. Abstract 151. Modeling the rise of intratumoral heterogeneity in growing, static, and regressing human colorectal polyps.

Mingyang Song, MD, ScD, Harvard University, Boston, MA. Abstract 1418. Marine ω-3 polyunsaturated fatty acid intake and risk of colorectal cancer according to tumor-infiltrating T cells.

Caroline Y. Um, MPH, Emory University, Atlanta, GA. Abstract 1758. Circulating insulin-like growth factors: Correlates and responses to calcium supplementation in colorectal adenoma patients.

2016 AACR-Susan G. Komen® Scholar-in-Training Awards

Susan G. Komen® has graciously donated funds to the AACR to support early-career investigators who will be presenting meritorious proffered papers relating to breast cancer research at the AACR Annual Meeting 2016.

Adrian Britschgi, PhD, Friedrich Miescher Institute for Biomedical Research, Basel, Switzerland. Abstract 3305. Hippo kinases LATS1/2 control human breast cell fate.

Uri Ben-David, PhD, The Broad Institute of MIT and Harvard, Cambridge, MA. Abstract 2683. The landscape of chromosomal aberrations in mouse models of breast cancer reveals driver-specific routes to tumor development.


Chi-Chih (Ginny) Kang, PhD, UC Berkeley, Berkeley, CA. Abstract 352. HER2 protein isoform heterogeneity investigated by single-cell western blotting.

Maeve Mullooly, PhD, MPH, National Cancer Institute, Bethesda, MD. Abstract 4283. Relationship between mammographic breast density and measures of terminal duct lobular unit involution among women diagnosed with estrogen receptor positive breast cancer.
Yashar S. Niknafs, BS, University of Michigan, Ann Arbor, MI. Abstract 2662. Interrogation of the landscape of long noncoding RNAs in breast cancer to identify an ER-regulated predictor of tamoxifen resistance.

Ciara H. O'Flanagan, PhD, University of North Carolina at Chapel Hill, Chapel Hill, NC. Abstract 1020. Autophagy forms part of a metabolic switch during epithelial-to-mesenchymal transition and metastasis in a murine claudin-low breast cancer model.

Hannah Oh, ScD, National Cancer Institute, Bethesda, MD. Abstract 3451. Breast cancer risk factor associations by loss of E-cadherin tumor tissue expression: A pooled analysis of 5,896 cases in 12 studies from the Breast Cancer Association Consortium (BCAC).


Matthew J. Sikora, PhD, University of Pittsburgh, Pittsburgh, PA. Abstract 862. WNT4 mediates endocrine response and resistance in invasive lobular carcinoma cell lines and patient tumor explants.

Stefan Werner, Dr. rer. nat., University Medical Center Hamburg-Eppendorf, Hamburg, Germany. Abstract 2733. Novel function of the RAI2 protein in genomic integrity of breast cancer cells.


2016 AACR-MEG Scholar-in-Training Awards

These awards are for meritorious proffered papers in molecular epidemiology that will be presented at the AACR Annual Meeting 2016, supported by the Molecular Epidemiology Working Group (MEG) of the AACR. The mission of MEG is to increase knowledge about cancer and chronic disease etiology, thereby promoting the prevention and treatment of cancer, and the improvement of public health. In addition to travel support, award recipients receive a free one-year membership in the Working Group.

David A. Drew, PhD, Massachusetts General Hospital, Boston, MA. Abstract 4348. A prospective study of smoking habit and risk of synchronous colorectal cancers.

Lesley S. Park, PhD MPH, Stanford University School of Medicine, Stanford, CA. Abstract 4308. Multiplicative interaction between HIV infection status and FIB-4 in prediction of hepatocellular carcinoma risk.

Lauren C. Peres, PhD, MPH, University of Virginia, Charlottesville, VA. Abstract 1754. Body powder use and ovarian cancer: the African American Cancer Epidemiology Study.
2016 AACR-Pezcoller Foundation Scholar-in-Training Awards

The Pezcoller Foundation supports these awards to enhance participation in the programs and activities of the AACR by early-career investigators residing in Europe and to provide these outstanding Scholar-in-Training Awardees with an opportunity to share their research findings with the international cancer research community at the AACR Annual Meeting.

Sara M. Bolin, MSc, Uppsala University, Uppsala, Sweden. **Abstract 2473.** Combined BET-bromodomain and CDK2 inhibition in MYC-driven medulloblastoma.

Patricia Fernandez Nogueira, PhD, Universitat de Barcelona, Barcelona, Spain. **Abstract 752.** Fibroblast growth factor receptor 2 - HER2 transactivation: Role of fibroblasts in the acquisition and maintenance of anti-Her2 target therapies resistance in breast cancer.

Matina Fragkogianni, MSc, MRC Centre for Reproductive Health, Queen’s Medical Research Institute, University of Edinburgh, Edinburgh, United Kingdom. **Abstract 2698.** Transcriptional profiling of human TAMs highlights differences in breast and endometrial tumor microenvironments.

Maria Jesus Ortiz Ruiz, PhD, Institute of Cancer Research, Sutton, United Kingdom. **Abstract 4355.** Elucidation of the different roles of CDK8 and CDK19 in colorectal cancer (CRC) using CRISPR gene editing technology.

Francesco Sabbatino, MD, PhD, University of Salerno, Salerno, Italy. **Abstract 4017.** Anti-tumor activity of a BRAF inhibitor and IFNα combination in BRAF mutant melanoma.

Lena Sokol, Dr. rer. nat., University of Bern, Bern, Switzerland. **Abstract 4135.** A signature of rejection in colorectal cancer: immune markers and their epigenetic regulation.

2016 AACR-Prostate Cancer Foundation Scholar-in-Training Awards

The Prostate Cancer Foundation has graciously donated funds to the AACR to support early-career investigators who will be presenting meritorious proffered papers relating to advanced prostate cancer at the AACR Annual Meeting 2016.

Haley D. Axelrod, BS, Johns Hopkins School of Medicine, Baltimore, MD. **Abstract 1572.** Overexpression of Axl delays metastatic outgrowth of prostate cancer bone marrow disseminated tumor cells.

Robert S. Gitman, BS, Thomas Jefferson University Hospital, Philadelphia, PA. **Abstract 23.** Caloric restriction slows tumor growth and metastases in both hormone-sensitive and hormone-resistant prostate cancers.

Min Zou, PhD, Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, New York, NY. **Abstract 4387.** Alterations of TP53 mediate resistance to abiraterone in castration-resistant prostate cancer.
2016 AACR-SIC Scholar-in-Training Awards

The AACR-SIC Scholar-in-Training Awards are a partnership between the AACR and the Società Italiana di Cancerologia (SIC, the Italian Cancer Society). The AACR and SIC sponsor these awards to enhance participation by early-career investigators who are members of SIC, and to provide these outstanding Scholar-in-Training Awardees with an opportunity to share their research findings with the international cancer research community at the AACR Annual Meeting.

Ezia Bello, MS, IRCCS Istituto di Ricerche Farmacologiche Mario Negri, Milan, Italy. **Abstract 1183.** PPARgamma agonist promotes adipocytic differentiation and potentiates the activity of trabectedin in myxoid liposarcoma.

Anastasia Chillà, MS, University of Florence, Firenze, Italy. **Abstract 5063.** The receptor for urokinase-plasminogen activator controls plasticity of cancer cell movement in mesenchymal and amoeboid migration style.

Orazio Fortunato, PhD, Fondazione IRCCS Istituto Tumori Milano, Milan, Italy. **Abstract 948.** Microenvironmental origin of circulating miRNAs in lung cancer.

Marilena V. Iorio, PhD, Fondazione IRCCS Istituto Tumori Milano, Milan, Italy. **Abstract 1068.** The promise of miR-205 in HER2+ breast cancer: predicting response to trastuzumab and overcoming resistance.

Caterina Mancarella, PhD, Rizzoli Orthopaedic Institute, Bologna, Italy. **Abstract 3201.** Insulin-like growth factor 2 (IGF-2) mRNA binding protein 3 predicts poor prognosis and promotes cell proliferation in Ewing sarcoma.

Silvia Menegon, PhD, IRCCS, Candiolo, Italy. **Abstract 622.** Gastric cancer in the age of targeted agents: identification and validation of novel therapeutic strategies through the generation of a patient-derived xenografts platform.

Arianna Palladini, PhD, University of Bologna, Bologna, Italy. **Abstract 1200.** HER-2 isoform interaction in mammary carcinoma onset and progression.

Simona Romano, PhD, University of Naples Federico II, Naples, Italy. **Abstract 2216.** Study of PDL-1 regulation and expression in glioblastoma and its role in cancer resistance.

Sarah Uboldi, MS, IRCCS Istituto di Ricerche Farmacologiche Mario Negri - Milano, Milan, Italy. **Abstract 4821.** The WEE1 inhibitor AZD-1775 has synergic activity with trabectedin or lurbinectedin in ovarian cancer cells.
2016 AACR Scholar-in-Training Award in Memory of Jodie Beth Skibicki

Gifts made in memory of Jodie Beth Skibicki have been graciously donated to support young investigators with high-quality proffered papers related to BRCA research at the AACR Annual Meeting 2016.

**Sahar J. Alothman, MSc**, Georgetown University, Washington, DC.  Abstract 656. Histological and 3D morphological evaluation of mammary cancers and primary cells from genetically engineered mice with only one copy of Brca1 disrupted in combination with Trp53 haploinsufficiency.

**Chiara Svetlana Brambillasca, MSc**, NKI-AVL, Amsterdam, Netherlands.  Abstract 889. Dissecting the role of MYC in BRCA1-associated breast cancer.

**Huai-Chin Chiang, PhD**, The University of Texas Health Science Center at San Antonio, San Antonio, TX.  Abstract 514. Effect of radiation therapy on breast epithelial cells in BRCA1/2 mutation carriers.

2016 AACR-Takeda Oncology Scholar-in-Training Awards

Takeda Oncology has graciously donated funds to support early-career investigators who will be presenting meritorious proffered papers at the AACR Annual Meeting 2016.

**Katherine B. Chiappinelli, PhD**, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins School of Medicine, Baltimore, MD.  Abstract 4019. Inhibiting DNA methylation causes an interferon response in cancer cells via endogenous retroviruses and recruits immune cells to the tumor microenvironment to sensitize to immune therapy.

**Samikshan Dutta, PhD**, University of Nebraska Medical Center, Omaha, NE.  Abstract 3526. Novel function of NRP2 in therapy resistant metastatic cancer.

**Liang Fei, PhD**, Weill Cornell Medicine, New York, NY.  Abstract 4163. Molecular and physiological effects of splicing factor mutant U2AF1 in human lung cell lines and in mice.

**Robert D. Leone, MD**, The Sidney Kimmel Comprehensive Cancer Research Center, Johns Hopkins University School of Medicine, Baltimore, MD.  Abstract 4364. Adenosine A2a Receptor blockade as a means of enhancing immune checkpoint inhibition and adoptive T-cell therapy.

**Ling Liu, BS**, Princeton University, Princeton, NJ.  Abstract 1013. Quantification of NADPH balance in cancer.

**Benjamin H. Lok, MD**, Memorial Sloan Kettering Cancer Center, New York, NY.  Abstract 3756. PARP inhibitor sensitivity in small cell lung cancer cell lines and patient-derived xenografts correlates with SLFN11 expression but not with structural homologous recombination deficiency.
Naga Poojitha Ojamies, MSc, Institute for Molecular Medicine Finland (FIMM), Helsinki, Finland. 
Abstract 2378. Responses of AML patients to tailored drug regimens: monitoring cancer subclones by ultra-deep resequencing.

Vito W. Rebecca, PhD, University of Pennsylvania, Philadelphia, PA. Abstract 1018. Structural features of novel dimeric quinacridines that have single-agent antitumor activity determine the mechanism of action: destabilization of mTORC1/lysosomal interaction versus DNA damage.

Sergio Rey, MD, PhD, Princess Margaret Cancer Centre, Toronto, ON, Canada. Abstract 2793. ADP-dependent glucokinase enhances hypoxia-inducible factor-α target gene transactivation through modulation of ROS levels in hypoxic human cancer cells.


Laura A. Stransky, BA, Tufts University, Boston, MA. Abstract 27. Understanding mechanisms of nutrient homeostasis: Amino acid availability and regulation of V-ATPase activity.

Kekoa A. Taparra, BS, Johns Hopkins University School of Medicine, Baltimore, MD. Abstract 1054. SNAI1 regulates the hexosamine biosynthetic pathway to promote tumorigenesis and oncogene-induced senescence escape in lung cancer.

Christopher J. Walker, PhD, The Ohio State University, Columbus, OH. Abstract 2002. MAX mutations in endometrial cancer are associated with poor patient outcome, altered E-box binding, and increased tumor vascularity.

Baiyu Yang, PhD, National Cancer Institute, Bethesda, MD. Abstract 818. Shortened telomere length in hepatocellular carcinoma in the United States.

2016 AACR-Triple Negative Breast Cancer Foundation Scholar-in-Training Awards

The Triple Negative Breast Cancer Foundation has graciously donated funds to support young investigators who will be presenting high-quality proffered papers on triple negative breast cancer research at the AACR Annual Meeting 2016.

Talha E. Anwar, BS, University of Michigan Medical School, Ann Arbor, MI. Abstract 4481. Phosphorylation regulates EZH2 neoplastic functions in triple-negative breast cancer.

Jennifer M. Brancato Sahni, BA, Case Western Reserve University, Cleveland, OH. Abstract 4647. BET protein inhibition blocks growth of triple-negative breast cancer by inducing mitotic and cytokinetic dysfunction.
Roman Camarda, BSc, University of California, San Francisco, San Francisco, CA. **Abstract 2673.** Inhibition of fatty-acid oxidation as a therapy for MYC-overexpressing triple-negative breast cancer.

Suzann Duan, BS, University of Nevada School of Medicine, Reno, NV. **Abstract 4275.** Exploring the metastatic potential of exosomal NM23 signaling using a triple negative breast cancer model in mice.

Gloria V. Echeverria, PhD, The University of Texas MD Anderson Cancer Center, Houston, TX. **Abstract 2406.** Identifying and targeting chemoresistant subclones in triple negative breast cancer.

Hui Liu, PhD, Harvard Medical School, Boston, MA. **Abstract 3858.** Feasibility and efficacy of a precision treatment approach for triple-negative breast cancer in mouse models.

Julie M. Madden, PhD, University of Michigan, Ann Arbor, MI. **Abstract 3236.** Macrophages increase the expression of RhoC in inflammatory breast cancer leading to increased migration.

Bernadette V. Marquez, PhD, Washington University School of Medicine, Saint Louis, MO. **Abstract 4209.** Targeting GPNMB with 89Zr-CR011 for PET imaging of triple negative breast cancer.

Thao Nguyen D. Pham, BA, University of Illinois, Chicago, IL. **Abstract 682.** PKCα mediates FOXC2 transcriptional repression of p120-catenin in breast cancer.

Mary Kathryn Pitner, PhD, The University of Texas MD Anderson Cancer Center, Houston, TX. **Abstract 1624.** Silencing of ERK2 reverses EMT and suppresses the CSC phenotype, inhibiting lung metastasis in triple-negative breast cancer.

Daniel C. Rabe, MS, University of Chicago, Chicago, IL. **Abstract 1557.** Metastasis suppressors regulate the tumor microenvironment by blocking recruitment of pro-metastatic TAMs.

Chetan K. Rane, BPharm, Rutgers University, Piscataway, NJ. **Abstract 1864.** In vivo efficacy of the PAK4 allosteric modulator KPT-9274 against a triple-negative breast cancer model.

Ruchi Roy, PhD, University of Pittsburgh, Pittsburgh, PA. **Abstract 833.** Benzyl isothiocyanate mediates glucose uptake through AKT activation in breast cancer cells.

Jinyoung Suh, MS, Seoul National University, Seoul, Korea, Republic of. **Abstract 4096.** Fibroblast growth factor-2-derived from cancer-associated fibroblasts stimulates proliferation and migration of human breast cancer cells.

Alice Turdo, PhD, University of Palermo, Palermo, Italy. **Abstract 3311.** Autocrine and paracrine IL-4 maintains breast cancer stem cells traits via RAS/MAPK/DUSP pathway.

Amanda E. D. Van Swearingen, PhD, University of North Carolina at Chapel Hill, Chapel Hill, NC. **Abstract 3867.** Combined PI3K and AURKA inhibition are efficacious in triple negative breast cancer models.
Jessica M. Wagner, BS, Fox Chase Cancer Center: Temple College of Medicine, Philadelphia, PA. **Abstract 3000.** Intra-tumoral accumulation of NK1.1/CD3+ cells and anti-metastasis effects of dose-intensified ONC201 in tumor-bearing mice.

2016 AACR-Warner Fund Scholar-in-Training Award

The Warner Fund has graciously donated funds to the AACR to support early-career investigators who will be presenting a proffered paper relating to cholangiocarcinoma.

Remco J. Molenaar, MSc, Academic Medical Center, Amsterdam, Netherlands. **Abstract 1659.** Radioprotection of IDH1-mutated solid tumor, but not leukemia cells by the IDH1-mutant inhibitor AGI5198.

Adwait Amod Sathe, MS, University of Texas at Dallas, Richardson, TX. **Abstract 773.** Analysis of oncogene affected networks in tumorigenesis of lung cancer.

2016 AACR Scholar-in-Training Award in Memory of Dr. Lee W. Wattenberg

The late Dr. Wattenberg, a pioneer in cancer prevention research, was a dedicated member of the AACR and served as President in 1992. Wattenberg was especially dedicated to supporting the professional development of early-career scientists. During his presidency, he launched the Associate Member Council. This Award is presented to young investigators presenting high-quality proffered papers relating to prevention research at the AACR Annual Meeting 2016.

Min Ji Bak, PhD, Rutgers University, Piscataway, NJ. **Abstract 5237.** Protection of tocopherols against estrogen-induced breast cancer via mechanisms targeting cancer stem cells.

Saraswoti Khadge, MSc, University of Nebraska Medical Center, Omaha, NE. **Abstract 4323.** Dietary omega-3 suppress mammary tumor growth, metastasis and enhances survival in an isocaloric pair-fed mice model.

Su Hyeong Kim, PhD, University of Pittsburg Cancer Institute, Pittsburgh, PA. **Abstract 822.** Role of c-Myc in prostate cancer stem-like cell inhibition by sulforaphane.

Ambrish Kumar, PhD, University of South Carolina School of Medicine, Columbia, SC. **Abstract 2605.** Metformin reduces growth of tumors generated from neuroblastoma stem cells in a xenograft mouse model; role of Cdc42 in mediating the effects.

Venkateshwar Madka, PhD, University of Oklahoma Health Sciences Center, Oklahoma City, OK. **Abstract 5241.** Nitric oxide-releasing naproxen prevents muscle invasive bladder cancer.
Subrata K. Pore, PhD, University of Pittsburgh, Pittsburgh, PA. Abstract 826. Benzyl isothiocyanate inhibits breast cancer-induced osteoclastogenesis.

Intiaz A. Siddiqui, PhD, University of Wisconsin-Madison, Madison, WI. Abstract 5263. Prostate specific membrane antigen (PSMA)-targeting nanobioconjugate-encapsulated green tea polyphenol EGCG for prostate cancer prevention and therapy.

Krishna B. Singh, PhD, University of Pittsburg Cancer Institute, Pittsburgh, PA. Abstract 831. c-Myc is a novel target of prostate cancer cell growth inhibition by honokiol.

2016 AACR Scholar-in-Training Award in Memory of Dr. Richard L. Welsh

Gifts made in memory of Dr. Richard L. Welsh have been graciously donated to support young investigators with high-quality proffered papers at the AACR Annual Meeting 2016.

Elshad Hasanov, MD, Texas A&M Health Science Center, Institute of Biosciences and Technology, Houston, TX. Abstract 1161. A new, therapeutically actionable target for the VHL E3 ubiquitin ligase in renal cell carcinoma.

Eun-Young Kho, MPH, PhD, University of Texas Southwestern, Dallas, TX. Abstract 53. Epigenetic silencing of Krebs cycle metabolism in kidney cancer.

David C. Muller, PhD, Imperial College London, London, United Kingdom. Abstract 4289. C-reactive protein and risk of lung cancer: A pooled analysis of 20 prospective cohorts.

Orestis A. Panagiotou, MD, PhD, National Cancer Institute, Rockville, MD. Abstract 3445. C-reactive protein and lung cancer risk: a Mendelian randomization analysis.

Daniel X. Yang, BS, Dana Farber Cancer Institute, Boston, MA. Abstract 3710. Synergy between PARP and Wee1 inhibitors suggests homologous recombination repair defect in NSCLC as a mechanistic target for combination therapy.

Liren Zhang, PhD, The University of Texas MD Anderson Cancer Center, Houston, TX. Abstract 809. Dietary iron intake, genetic variants in microRNA related iron regulatory pathway genes, and the risk of non-small cell lung cancer.